±ÇÇý¿ø(Kwon Hye-Won) - Seoul National University Children¡¯s Hospital Department of Pediatrics
(Suh Yoon-Jung) - Seoul National University Children¡¯s Hospital Department of Pediatrics
¹æÁö¼®(Bang Ji-Seok) - Seoul National University Children¡¯s Hospital Department of Pediatrics
±Çº¸»ó(Kwon Bo-Sang) - Seoul National University Children¡¯s Hospital Department of Pediatrics
±è±â¹ü(Kim Gi-Beom) - Seoul National University Children¡¯s Hospital Department of Pediatrics
¹èÀºÁ¤(Bae Eun-Jung) - Seoul National University Children¡¯s Hospital Department of Pediatrics
±è¿õÇÑ(Kim Woong-Han) - Seoul National University Children¡¯s Hospital Department of Thoracic and Cardiovascular
³ëÁ¤ÀÏ(Noh Chung-Il) - Seoul National University Children¡¯s Hospital Department of Pediatrics
Abstract
Takayasu arteritis is a chronic inflammatory disease of unknown etiology primarily affecting the aorta and its major branches and usually occurring in the second or third decade of life. Here, we report a case of Takayasu arteritis in a 10-month-old patient. The infant presented with signs of congestive heart failure and severe aortic regurgitation. Echocardiography and computed tomography angiography showed an abnormally dilated thoracic and abdominal aorta. The infant was initially treated with prednisolone, followed by commissuroplasty of the aortic valve but neither approach ameliorated the heart failure. The patient was eventually treated with a mechanical aortic valve replacement surgery at the age of 12 months, and her condition stabilized. Although unusual, this case indicates that the diagnosis of Takayasu arteritis should be considered in children with unexplained systemic symptoms, aortic valve regurgitation, and heart failure. Because severe aortic regurgitation may be a fatal complication of Takayasu arteritis, early aortic valve replacement surgery should be considered, even in very young children.
Å°¿öµå
Aortic valve insufficiency, Takayasu arteritis
KMID :
1130320120550070254
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Because AR is a potentially fatal complication of TA, early and aggressive aortic valve replacement surgery with perioperative immunosuppressive therapy should be considered.